文献速递消化道肿瘤放疗

G9a通过PP2A-RPA轴调控结肠癌干细胞表型及放化疗抵抗

G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response.
PubMed 文献 · Radiother Oncol · 2017-03-25

该研究探讨组蛋白甲基转移酶G9a在结肠癌干细胞表型及放化疗抵抗中的作用。研究纳入39例接受新辅助同步放化疗的直肠癌患者原发肿瘤标本,结合体内异种移植模型和体外成球实验。结果显示放疗存活细胞高表达G9a,且G9a与干细胞标志物CD133呈显著正相关;敲低G9a经PP2A-RPA轴增加细胞对放疗和DNA损伤剂的敏感性。

要点

  • 放疗存活结肠癌细胞高表达G9a,G9a与CD133在直肠癌放化疗患者中呈显著正相关
  • 敲低G9a经PP2A-RPA轴增加细胞对放疗及DNA损伤剂的敏感性
  • G9a有望作为预测结肠癌术前放化疗反应的新靶点

核心结论

  • G9a可能作为结肠癌新靶点,有望预测晚期结直肠癌患者对术前放化疗的反应。

研究设计与样本

  • 选取39例接受同步放化疗的直肠癌患者原发肿瘤标本,并建立免疫缺陷小鼠体内异种移植模型及体外成球实验。

主要发现

  • 放疗存活细胞显示高水平G9a,G9a与干细胞标志物CD133在接受放化疗的局部晚期直肠癌患者中呈显著正相关。
  • 敲低G9a增加细胞对放疗的敏感性,并经PP2A-RPA轴使细胞对DNA损伤剂敏感。

临床怎么用

  • G9a表达或可辅助预测局部晚期结直肠癌术前同步放化疗反应,以避免过度治疗和不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Neoadjuvant concurrent chemoradiotherapy (CCRT) is a standard treatment of locally advanced colon cancer cell (CRC). In order to maximize efficacy and minimize toxicity, new drugs have been developed and used in combination with CCRT. Recently, it has been shown that G9a plays a role in mediating phenotypes of cancer stem cells (CSCs). This study aimed to characterize G9a as a biomarker in predicting therapy response to prevent overtreatment and adverse effects in CRC patients. EXPERIMENTAL DESIGN: The primary tumors from 39 patients who received CCRT for rectal cancer were selected. In vivo tumor xenograft models for tumorigenic properties in immunodeficient mice were developed. In vitro stemness ability was performed by tumor-sphere assays, cell response to anti-cancer agents and stemness-related genes analysis. RESULTS: Cells survived from radiation treatment, and displayed high levels of G9a. A significantly positive correlation was shown between G9a and CSCs marker CD133 in locally advanced rectal cancer patients with CCRT. Knockdown of G9a increased the sensitivity of cells to radiation treatment and sensitized cells to DNA damage agents through PP2A-RPA axis. CONCLUSIONS: Our study theorized that G9a might serve as a novel target in colon cancer, which offers exciting potential in prediction of response to preoperative chemoradiotherapy in patients with advanced CRC.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Luo CW, Wang JY, Hung WC, et al. G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response. Radiother Oncol. 2017. PMID: 28351524. doi:10.1016/j.radonc.2017.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。